Education
About Us
Working with TipRanks
Follow Us
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
CPIX Stock Chart & Stats
$4.38
-$0.13(-5.49%)
At close: 4:00 PM EST
$4.38
-$0.13(-5.49%)
Day’s Range― - ―
52-Week Range$1.85 - $7.25
Previous CloseN/A
Volume23.17K
Average Volume (3M)27.29K
Market Cap
$61.62M
Enterprise Value$44.06M
Total Cash (Recent Filing)$15.20M
Total Debt (Recent Filing)$10.24M
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Mar 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding14,956,627
10 Day Avg. Volume30,352
30 Day Avg. Volume27,288
Financial Highlights & Ratios
PEG Ratio-1.13
Price to Book (P/B)1.46
Price to Sales (P/S)0.88
P/FCF Ratio-42.08
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue1.07
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda16.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cumberland Pharmaceuticals News
CPIX FAQ
What was Cumberland Pharmaceuticals Inc’s price range in the past 12 months?
Cumberland Pharmaceuticals Inc lowest stock price was $1.85 and its highest was $7.25 in the past 12 months.
What is Cumberland Pharmaceuticals Inc’s market cap?
Cumberland Pharmaceuticals Inc’s market cap is $61.62M.
When is Cumberland Pharmaceuticals Inc’s upcoming earnings report date?
Cumberland Pharmaceuticals Inc’s upcoming earnings report date is Mar 10, 2026 which is in 71 days.
How were Cumberland Pharmaceuticals Inc’s earnings last quarter?
Cumberland Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.13.
Is Cumberland Pharmaceuticals Inc overvalued?
According to Wall Street analysts Cumberland Pharmaceuticals Inc’s price is currently Overvalued.
Does Cumberland Pharmaceuticals Inc pay dividends?
Cumberland Pharmaceuticals Inc does not currently pay dividends.
What is Cumberland Pharmaceuticals Inc’s EPS estimate?
Cumberland Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cumberland Pharmaceuticals Inc have?
Cumberland Pharmaceuticals Inc has 14,956,627 shares outstanding.
What happened to Cumberland Pharmaceuticals Inc’s price movement after its last earnings report?
Cumberland Pharmaceuticals Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.406%.
Which hedge fund is a major shareholder of Cumberland Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in CPIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cumberland Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
168.75%
12-Months-Change
Fundamentals
Return on Equity
-13.08%
Trailing 12-Months
Asset Growth
-13.52%
Trailing 12-Months
Company Description
Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc. (CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development and commercialization of innovative and high-quality prescription products. The company primarily operates in the pharmaceutical sector, concentrating on the areas of pain management and hospital-based therapies. Its core products include Acetadote, a treatment for acetaminophen overdose, and Vaprisol, a therapy for hyponatremia, among others. Cumberland's mission is to deliver meaningful solutions for patients and healthcare providers through its specialized product offerings.
CPIX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strategic partnerships and international expansion, alongside strong revenue growth and clinical progress, which were slightly offset by shipment delays and increased competition. Overall, the sentiment of the call was positive, with more highlights than lowlights.View all CPIX earnings summariesTechnical Analysis
Assertio Therapeutics
―
Rockwell Med
―
SCYNEXIS
―
KALA BIO
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
41.61% Insiders
5.06% Mutual Funds
6.58% Other Institutional Investors
43.63% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---